good people Great Lawyers Start Your Free Consultation

Melissa Hague Appointed to Zofran Plaintiffs’ Steering Committee

Posted By ilawyer on this December 30, 2015 at 12:12 pm

2569386_1.jpegAnapol Weiss attorney Melissa Hague has been appointed by U.S. District Judge F. Dennis Saylor IV to serve on the Plaintiffs’ Steering Committee (PSC) in In Re: Zofran (Ondansetron) Products Liability Litigation, MDL 2657. The Zoran PSC is made up of 14 lawyers from firms all over the country who are experienced in leading mass tort litigation.

The PSC will work tirelessly to protect the rights of those who have filed lawsuits on behalf of children who developed birth defects caused by Zofran, a medication prescribed to pregnant mothers for nausea and vomiting. The PSC has been charged with initiating and conducting all pretrial discovery, responding to and drafting motions, managing and presenting common issues for trial through a bellwether process, and negotiating and proposing reasonable settlement options for the common benefit of all plaintiffs with cases in the MDL. The PSC plans on meeting internally on a regular basis and with opposing counsel to ensure that the litigation moves efficiently and the rights of these victims are zealously pursued.

A Diligent Mass Tort Lawyer

Melissa Hague has dedicated her career to the successful prosecution of complex mass tort cases. She has successfully represented and continues to represent hundreds of people injured by defective metal-on-metal hip implants as well as knee implants. Melissa also had an integral role in the resolution of the In re: Human Tissue Products Liability Litigation involving victims who received infected and improperly screened cadaver bone and tissue.

Zofran Linked to Birth Defects

Some pregnant mothers were prescribed Zofran to stop the effects of morning sickness. However, the drug has been linked to increasing an unborn baby’s risk of developing birth defects including cleft lip and palate as well as certain heart defects.

Topics Uncategorized

Leave a Reply